Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
基本信息
- 批准号:8610310
- 负责人:
- 金额:$ 35.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-16 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAffectAllelesAmericanAnimalsAntifungal AgentsApoptosisAutomobile DrivingAzolesBasal Cell Nevus SyndromeBasal cell carcinomaCell LineCell SurvivalCellsClinical TrialsCommunicationComplexDataDefectDevelopmentDiagnosisDrug CombinationsDrug TargetingEmbryonic DevelopmentErinaceidaeEventExposure toFDA approvedGenesGeneticGenetic EngineeringGerm-Line MutationGrowthHealth Care CostsHereditary DiseaseHomeostasisHumanHuman DevelopmentInborn Genetic DiseasesIncidenceIndividualInduced MutationItraconazoleKnowledgeLaboratoriesLuciferasesMalignant Epithelial CellMalignant NeoplasmsMediatingMicroscopicModelingMolecularMolecular TargetMusMutationNewborn InfantPTCH genePathogenesisPathway interactionsPatientsPerifosinePharmaceutical PreparationsPhasePhosphorylationPreventionRegimenRegulatory PathwayResistanceRiskSafetySecondary toSignal PathwaySignal TransductionSignal Transduction PathwaySignaling ProteinSkinSonic Hedgehog PathwayTestingTherapeuticTherapeutic AgentsTissuesToxic effectTumor Suppressor ProteinsUV inducedUVB inducedUltraviolet B RadiationUltraviolet RaysUnited Statesbasecombinatorialdesignhuman FRAP1 proteinhuman diseasein vitro Assayinhibitor/antagonistinnovationinsightkeratinocyteknock-downmedulloblastomamouse modelnovelnovel therapeutic interventionpre-clinicalpreventsmall moleculesmoothened signaling pathwaytranscription factortumortumor growthtumor progressionultraviolet
项目摘要
DESCRIPTION (provided by applicant): Basal cell carcinomas (BCCs) are the most common type of human malignancy in the United States; more than 1,000,000 Americans are diagnosed with BCCs each year. The management of these tumors is a major contributor to health care costs. BCC risk directly correlates with exposure to environmental solar ultraviolet (UV) radiation
and these tumors manifest activated sonic hedgehog (Shh) signaling and Shh is among the most fundamental signal transduction pathways in embryonic development. Activated Shh signaling secondary to inactivating germline mutations in Ptch, the repressor of this pathway, characterizes both human and murine BCCs. This is associated with the rare, dominantly inherited disorder known as Gorlin syndrome. These patients develop large numbers of BCCs in addition to developing various extracutaneous tumors such as medulloblastomas. Knowledge of the importance of Shh signaling in driving BCC pathogenesis has led to the identification of small molecules that target different components of this pathway including Smo, Shh, and Gli-1. However, because the Shh signaling pathway is indispensable for development and tissue homeostasis, the potential toxicity of Shh inhibitors is an important consideration for human use. Moreover, both preclinical and our recently-completed clinical trials indicate that simply targetin the Shh pathway does not totally block the proliferation of BCC cells, suggesting that additional pathway(s) may contribute to BCC pathogenesis. We have generated preliminary data showing efficacious suppression of the growth of UVB-induced BCCs by simultaneously inhibiting the Shh and Akt1 and mTOR pathways thereby implicating Akt1-mTOR signaling in BCC development. Furthermore, we have shown that the Shh pathway directly regulates mTOR expression and that mTOR is a direct transcriptional target of SOX9, a transcription factor regulated by Gli-1. In this proposal we will test the hypothesis that there are cooperative interactions between Akt1 and Shh pathways that converge on mTOR, and that blocking both Shh and Akt1 pathways is necessary to successfully block BCC pathogenesis. Using both in vitro assays and BCC murine models generated in our laboratory to recapitulate Gorlin syndrome (Ptch1+/-/SKH-1 and Akt KO/Ptch1+/-/SKH-1, and Gli-luciferase/Ptch+/-/SKH-1), we will (1) define the importance of Akt1 in the pathogenesis of BCCs, (2) determine the mechanism of the cooperative interactions between Akt1 and Shh pathways in regulating mTOR, and (3) test the use of combinations of therapeutic agents capable of targeting both pathways simultaneously. The studies proposed here have substantial potential to provide important insights into the mechanisms underlying signaling events that drive the pathogenesis of BCCs. By utilizing non-toxic targeted agents in various combinations, it is likely that we can develop novel therapeutic approaches for preventing/treating human BCCs.
描述(由申请人提供):基底细胞癌(BCC)是美国最常见的人类恶性肿瘤类型;每年有超过 1,000,000 名美国人被诊断患有 BCC。这些肿瘤的治疗是医疗保健费用的主要来源。 BCC 风险与暴露于环境太阳紫外线 (UV) 辐射直接相关
这些肿瘤表现出激活的声波刺猬(Shh)信号传导,而Shh是胚胎发育中最基本的信号转导途径之一。继发于 Ptch 种系突变失活后激活的 Shh 信号传导,Ptch 是该途径的抑制因子,是人类和小鼠 BCC 的特征。这与一种罕见的显性遗传性疾病——戈林综合征有关。这些患者除了出现各种皮外肿瘤(例如髓母细胞瘤)外,还会出现大量基底细胞癌。由于了解了 Shh 信号传导在驱动 BCC 发病机制中的重要性,因此鉴定出了针对该通路不同成分的小分子,包括 Smo、Shh 和 Gli-1。然而,由于Shh信号通路对于发育和组织稳态不可或缺,因此Shh抑制剂的潜在毒性是人类使用的一个重要考虑因素。此外,临床前试验和我们最近完成的临床试验都表明,简单地靶向 Shh 通路并不能完全阻止 BCC 细胞的增殖,这表明其他通路可能有助于 BCC 发病机制。我们生成的初步数据显示,通过同时抑制 Shh、Akt1 和 mTOR 通路,可有效抑制 UVB 诱导的 BCC 生长,从而表明 Akt1-mTOR 信号传导参与 BCC 的发展。此外,我们还表明,Shh 通路直接调节 mTOR 表达,并且 mTOR 是 SOX9(受 Gli-1 调节的转录因子)的直接转录靶标。在本提案中,我们将测试以下假设:Akt1 和 Shh 通路之间存在协同相互作用,并汇聚于 mTOR,并且阻断 Shh 和 Akt1 通路对于成功阻断 BCC 发病机制是必要的。使用体外测定和我们实验室生成的 BCC 小鼠模型来概括 Gorlin 综合征(Ptch1+/-/SKH-1 和 Akt KO/Ptch1+/-/SKH-1 和 Gli-荧光素酶/Ptch+/-/SKH-1),我们将 (1) 定义 Akt1 在 BCC 发病机制中的重要性,(2) 确定 Akt1 在 BCC 发病机制中的重要性,(2) 确定 Akt1 在 BCC 发病机制中的重要性。 Akt1 和 Shh 通路在调节 mTOR 方面的协同相互作用,以及 (3) 测试能够同时靶向这两种通路的治疗药物组合的使用。这里提出的研究具有巨大的潜力,可以为驱动 BCC 发病机制的信号事件背后的机制提供重要见解。通过利用各种组合的无毒靶向药物,我们有可能开发出预防/治疗人类基底细胞癌的新治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID RINSEY BICKERS其他文献
DAVID RINSEY BICKERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID RINSEY BICKERS', 18)}}的其他基金
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
肿瘤免疫分析可优化基底细胞痣综合征的临床试验准备
- 批准号:
10046642 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
- 批准号:
10552026 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
- 批准号:
10330598 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
Molecular Mechanisms Underlying the Prevention of BCC Resistance
预防 BCC 耐药性的分子机制
- 批准号:
9974157 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
Tumor Immune Profiling to Optimize Clinical Trial Readiness in Basal Cell Nevus Syndrome
肿瘤免疫分析可优化基底细胞痣综合征的临床试验准备
- 批准号:
10221074 - 财政年份:2020
- 资助金额:
$ 35.64万 - 项目类别:
Columbia University Skin Disease Resource-Based Center (epiCURE)
哥伦比亚大学皮肤病资源中心 (epiCURE)
- 批准号:
9087989 - 财政年份:2016
- 资助金额:
$ 35.64万 - 项目类别:
Columbia University Skin Disease Resource-Based Center (epiCURE)
哥伦比亚大学皮肤病资源中心 (epiCURE)
- 批准号:
9765045 - 财政年份:2016
- 资助金额:
$ 35.64万 - 项目类别:
Non-melanoma skin cancer: A model for impact of aging on an environmental disease
非黑色素瘤皮肤癌:衰老对环境疾病影响的模型
- 批准号:
9204120 - 财政年份:2016
- 资助金额:
$ 35.64万 - 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
- 批准号:
8460080 - 财政年份:2012
- 资助金额:
$ 35.64万 - 项目类别:
Mechanism-based abrogation of BCC pathogenesis
基于机制的 BCC 发病机制的消除
- 批准号:
8296459 - 财政年份:2012
- 资助金额:
$ 35.64万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Research Grant